Karolinska Development

Transaction in Own Shares • Dec 16, 2015

Karolinska Development – sale of own shares to cover social security fees related to 2012 incentive program

STOCKHOLM - December 16, 2015. The Board of Directors of Karolinska Development has decided – within the authorization from the Annual General Meeting on May 20, 2015 – to sell a maximum of 20,000 Series B shares to cover the cost of social security fees related to the 2012 employee incentive program.

The sale will be made from December 16, 2015 to May 24, 2016, which is the day before the Annual General Meeting 2016. The sale of shares shall take place on NASDAQ OMX Stockholm and may only occur at a price within the price interval registered at each time for the share. The share price interval is the price interval between the highest buying price and the lowest selling price.

The purpose of the sale is to cover charges in the form of social security fees that relate to the PSP 2012 incentive program which was approved at the Annual General Meeting on May 23, 2012. Prior to the above decision, Karolinska Development holds 239,285 Series B shares.

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and cofunded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This constitutes information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is legally obliged to publish under the Securities Market Act and/or the Financial Instruments Trading Act.